secwatch.observer — SEC 8-K summary
======================================

Issuer:     AN2 Therapeutics, Inc. (ANTX)
CIK:        0001880438
Form:       8-K
Filed at:   2024-11-05T23:59:59+00:00
Accession:  0001193125-24-251240
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

AN2 Therapeutics appoints Joshua Eizen as Chief Legal Officer and COO
---------------------------------------------------------------------

- Joshua Eizen appointed Chief Legal Officer and Chief Operating Officer effective Nov 4, 2024.
- Salary increased to $450,000; granted option for 63,000 shares and 31,500 RSUs.
- Option vests monthly over 48 months; RSUs vest annually over 4 years.
- Eizen previously served as Chief Legal Counsel; no family relationships or related-party transactions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1880438/000119312524251240/0001193125-24-251240-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1880438/000119312524251240/d872811d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-251240

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer